• What is it:
    • A solitary pulmonary nodule (SPN) is a single, well-circumscribed lesion within the lung parenchyma, measuring ?3 cm in diameter, surrounded by normal lung tissue, and not associated with other abnormalities like atelectasis or lymphadenopathy.
    • SPNs are commonly detected incidentally on imaging.
  • Etymology:
    • Derived from the Latin word solitarius, meaning “alone,” referring to the presence of a single lesion.
  • AKA:
    • Coin lesion.
  • Abbreviation:
    • SPN (Solitary Pulmonary Nodule).
  • How does it appear on each relevant imaging modality:
    • Chest CT (preferred):
      • Parts: Typically a single, isolated lesion; may be solid, part-solid, or ground-glass (GGN).
      • Size: Defined as ?3 cm; larger lesions are classified as masses.
      • Shape: Round or oval with well-defined or irregular margins.
      • spiculated raises concern for malignancy but not pathognomonic
      • Position:
        • Can occur in any lung lobe;
        • sometimes bronchocentric
      • Character:
        • Calcifications: Benign patterns include central, laminated, or popcorn-like.
        • eccentric calcifications
          • raise the possibility of scar carcinoma.
        • Enhancement:
          • Malignant nodules show significant contrast enhancement (>15 HU).
    • Chest X-ray:
      • Appears as a
        • single,
        • round opacity,
        • well-defined or
        • slightly irregular, but smaller nodules may be missed.
    • PET-CT:
      • Increased SUV uptake (>2.5) is suspicious  malignancy.
      • SUV – 3-4 highly suspicious
      • False positives can occur with infections or inflammation.
  • Differential diagnosis
    • Infection
      • Granulomas (e.g., tuberculosis, histoplasmosis, coccidioidomycosis).
      • septic emboli
      • pulmonary abscess (in early stages).
    • Inflammation:
      • Rheumatoid nodule.
      • Sarcoidosis.
    • Neoplasm:
      • Benign: Hamartoma.
      • Malignant: Primary lung cancer (e.g., adenocarcinoma, squamous cell carcinoma).
    • Circulatory: Pulmonary infarct (can mimic an SPN).
    • Idiopathic: Cryptogenic organizing pneumonia (COP).
    • Iatrogenic: Post-radiation fibrosis presenting as a nodule.
  • Recommendations:
    • Further evaluation:
      • Low-dose chest CT for detailed characterization and follow-up.
      • PET-CT for SPNs ?8 mm to assess metabolic activity.
      • Biopsy (CT-guided or bronchoscopic) for indeterminate or suspicious nodules.
    • Surveillance:
      • Follow-up intervals based on size, density, and patient risk factors per Fleischner Society guidelines.
  • Key considerations and pearls:
    • SPNs <6 mm in low-risk patients generally do not require routine follow-up.
    • Benign SPNs often show specific calcification patterns or fat content (e.g., hamartomas).
    • Malignant SPNs are more likely in older patients, smokers, or those with a history of cancer.
    • Upper lobe SPNs, spiculated margins, and rapid growth (doubling time <30-400 days) are concerning for malignancy.
    • Clinical history and risk assessment are crucial in guiding the workup of SPNs.